The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgTDCS? 3) Can the use of mgTDCS significantly improve scores on neuropsychological tests of working memory?

开始日期2024-08-01

申办/合作机构

University of South Alabama

NCT06214468 / Recruiting临床1期IIT

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental. In space, astronauts who have pain and constant discomfort use acetaminophen extensively. Investigators are studying the effects of acetaminophen under space-like conditions since acetaminophen might affect astronauts' health. Investigators also wish to see whether a dietary supplement can reduce some negative effects of acetaminophen.
It is believed that acetaminophen promotes the productions of chemicals in the body that could be toxic.
In this study, measurements of these chemicals in urine after ingestion of 1 tablet of acetaminophen and compare these measurements to when acetaminophen is taken at the same time as a dietary supplement. This study will also explore whether these products are more abundant when blood is placed under conditions that mimic space. Therefore, this study will collect blood from a few volunteers who took acetaminophen, and acetaminophen with the dietary supplement.

开始日期2024-01-15

申办/合作机构

University of South Alabama

[+4]

NCT05987306 / RecruitingN/AIIT

A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss

The goal of clinical trial is to test a novel weight loss approach combining a standard weight loss and internalized weight bias intervention with self-compassion exercises in overweight adults with moderate to high levels of internalized weight bias. The main question[s] it aims to answer are: 1) Can participants lose significant weight loss and 2) significantly reduce internalized weight bias. Participants will take part in a 12 week novel weight loss approach combining a standard weight loss and internalized weight bias intervention with self-compassion exercises using videoconferencing software.

开始日期2023-09-24

申办/合作机构

East Carolina University

[+1]

100 项与 University of South Alabama 相关的临床结果

登录后查看更多信息

0 项与 University of South Alabama 相关的专利（医药）

登录后查看更多信息

8,579

项与 University of South Alabama 相关的文献（医药）

2024-12-31·European journal of psychotraumatology

So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs

Review

作者: Owen, Tyler ; Borgogna, Nicholas C ; Johnson, David A L ; Aita, Stephen L ; Vaughn, Jacob ; Hill, Benjamin D

Background: PTSD is a significant mental health problem worldwide. Current evidence-based interventions suffer various limitations. Ketamine is a novel agent that is hoped to be incrementally better than extant interventions.Objective: Several randomized control trials (RCTs) of ketamine interventions for PTSD have now been published. We sought to systematically review and meta-analyse results from these trials to evaluate preliminary evidence for ketamine's incremental benefit above-and-beyond control interventions in PTSD treatment.Results: Omnibus findings from 52 effect sizes extracted across six studies (n = 221) yielded a small advantage for ketamine over control conditions at reducing PTSD symptoms (g = 0.27, 95% CI = 0.03, 0.51). However, bias-correction estimates attenuated this effect (adjusted g = 0.20, 95%, CI = -0.08, 0.48). Bias estimates indicated smaller studies reported larger effect sizes favouring ketamine. The only consistent timepoint assessed across RCTs was 24-hours post-initial infusion. Effects at 24-hours post-initial infusion suggest ketamine has a small relative advantage over controls (g = 0.35, 95% CI = 0.06, 0.64). Post-hoc analyses at 24-hours post-initial infusion indicated that ketamine was significantly better than passive controls (g = 0.44, 95% CI = 0.03, 0.85), but not active controls (g = 0.24, 95% CI = -0.30, 0.78). Comparisons one-week into intervention suggested no meaningful group differences (g = 0.24, 95% CI = 0.00, 0.48). No significant differences were evident for RCTs that examined effects two-weeks post initial infusion (g = 0.17, 95% CI = -0.10, 0.44).Conclusions: Altogether, ketamine-for-PTSD RCTs reveal a nominal initial therapeutic advantage relative to controls. However, bias and heterogeneity appear problematic. While rapid acting effects were observed, all control agents (including saline) also evidenced rapid acting effects. We argue blind penetration to be a serious concern, and that placebo is the likely mechanism behind reported therapeutic effects.

2024-12-01·CURRENT OPINION IN BIOTECHNOLOGY

Phosphate-binding proteins and peptides: from molecular mechanisms to potential applications

Review

作者: Venkiteshwaran, Kaushik ; McLamore, Eric S ; Torres, Maria ; Hutchison, Justin M ; Mayer, Brooke K

Selective binding of phosphate is vital to multiple aims including phosphate transport into cells and phosphate-targeted applications such as adsorption-based water treatment and sensing. High-affinity phosphate-binding proteins and peptides offer a nature-inspired means of efficiently binding and separating phosphate from complex matrices. The binding protein PstS is characterized by a Venus flytrap topology that confers exceptional phosphate affinity and selectivity, and is effective even at low phosphate concentrations, all of which are essential for applications such as phosphate sensing, removal, and recovery. The binding event is reversible under controlled conditions, making it germane to catch-and-release objectives that advance phosphorus sustainability. Peptides such as the P loop motif are also promising for such applications. Future advances in protein/peptide design can contribute to increased implementation in engineered systems.

2024-12-01·Journal of cancer survivorship : research and practice

The impact of a meditative movement practice intervention on short- and long-term changes in physical activity among breast cancer survivors

Article

作者: James, Dara L ; Soltero, Erica G ; Larkey, Linda K ; Han, SeungYong

PURPOSE:

Tai Chi Easy (TCE) is a low-impact, meditative movement practice that is feasible for breast cancer survivors, even in the face of post-treatment symptoms, and may even serve as a gateway into developing an active lifestyle and improving overall physical activity (PA). In the context of a randomized controlled trial testing effects of an 8-week TCE intervention on breast cancer survivors' symptoms, we examined the short- (8-week) and long-term (9-month) impact on total PA compared to an educational control group.

METHODS:

Participants were recruited from two hospital systems, local community organizations, and different media platforms. Eligible participants were predominant non-Hispanic White (82%), college educated (92%), and middle- to high-income (65%), and most commonly reported stage 1 (40%) or 2 breast cancer (38%). After baseline assessments, participants were randomized to the 8-week TCE intervention (N=51) or education control (N=53). Weekly intervention TCE classes were led by a trained instructor. Weekly educational control classes focused on a series of readings and group discussions. Total PA and steps were objectively measured via accelerometry, and the international physical activity questionnaire was used to measure self-reported total PA.

RESULTS:

Multilevel mixed-effects linear regression models revealed no significant short- or long-term changes in objectively measured total PA or steps in either group; however, participants in the intervention reported short- and long-term changes in self-reported total PA.

CONCLUSIONS:

TCE is an appropriate PA strategy for survivors that may lead to modest improvements in PA; however, more research is needed to examine the long-term impact on PA as well as other physical and psychological outcomes (i.e., flexibility, mobility, stress).

IMPLICATIONS FOR CANCER SURVIVORS:

Low-impact, low-intensity activities like meditative movement practices are needed to assist survivors in overcoming post-treatment physical and psychological limitations to initiate a more active lifestyle.

项与 University of South Alabama 相关的新闻（医药）

2024-10-31

·PRNewswire

Uwill Wins Best Mental Health Technology

Merit Awards recognize mental health leader with top honors in healthcare category for its impact on student mental health NATICK, Mass., Oct. 31, 2024 /PRNewswire/ -- Uwill, the leading mental health and wellness solution for colleges and students, was honored as the 2024 Merit Awards for Healthcare 'Gold' winner for 'Best Mental Health Technology'. "The 2024 Healthcare winners represent the absolute best in healthcare innovation," said Marie Zander, Executive Director of the Merit Awards. "These pioneers are setting a high bar for the future of healthcare, and we are honored to recognize their exceptional contributions." The Merit Awards Healthcare program honors organizations that have made significant contributions to healthcare across a range of categories. The winners were selected by a distinguished panel of industry experts for their remarkable achievements in improving healthcare delivery and innovation. "Our team is honored to receive this award, which underscores our commitment to offering immediate mental health and wellness support, eliminating all barriers to care," said Michael London, Founder and CEO of Uwill. "We're dedicated to meeting the mental health needs of all students. This award reflects the positive impact our technology and our counselor community have made on campuses nationwide." Utilizing its proprietary technology and counselor team, Uwill pioneered the first student and therapist matching platform. The solution offers an immediate appointment with a licensed counselor based on student preferences, all modalities of teletherapy, a direct crisis connection, wellness events, realtime data, and support. Uwill serves more than 3 million students from all 50 states at institutions including Rutgers University, the Alabama Community College System, Morgan State University, and University of California, Santa Barbara. About Uwill: Uwill is the leading mental health and wellness solution for colleges and students, and the 27th fastest growing private company in the nation. As the most cost-effective way to enhance a college's mental health offering, Uwill partners with more than 400 institutions, including Princeton University, the Ohio State University, Santa Fe Community College, and University of Alabama - Online. Uwill is also the exclusive teletherapy education partner for the Online Learning Consortium and teletherapy education partner of NASPA. For more information, visit uwill.com. Contact: Brett Silk [email protected] SOURCE Uwill, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-10

·GlobeNewswire-Health Care

Endomimetics™ Awarded $300 Thousand Phase I SBIR Grant to Automate and Evaluate a Novel 3D in vitro model for use in Atherosclerosis drug Discovery and Development

Funding will support automation and large-scale fabrication of nanomatrix vascular sheet with atherosclerosis (VSA) functional assay plus its evaluation for use in drug efficacy and safety research Three-layer nanomatrix VSA innovation described in Biomaterials BIRMINGHAM, Ala., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Endomimetics, the developer of Bionanomatrix™, a peptide-based biomaterial to promote healing and improve outcomes following medical device implantation and other procedures, today announced the awarding of a $300 thousand Phase I Small Business Innovation Research (SBIR) grant to support automation and evaluation of a novel 3D in vitro functional assay for use in atherosclerosis drug discovery and development. The underlying innovation is a three-layer nanomatrix vascular sheet with atherosclerosis (VSA) that was described in Biomaterials (2024 Mar:305:122450. doi: 10.1016/j.biomaterials.2023.122450. Epub 2023 Dec 27). “Current In vitro atherosclerosis drug discovery models have significant limitations, such as the lack of a three-layer vascular architecture and limited atherosclerotic features,” said Ho-Wook Jun, Ph.D., Chief Scientific Officer of Endomimetics, Professor in the University of Alabama (UAB) Department of Biomedical Engineering and corresponding author of the Biomaterials paper. “Moreover, no scalable, high through-put 3D atherosclerosis assay is available for the evaluation of potential therapeutics. Availability of an automated approach for rapid and large-scale fabrication of a VSA assay should provide drug developers a highly reproducible functional assay to test their drug candidates in development to treat atherosclerosis.” The Phase I SBIR grant provides funding to support further advancement of the VSA technology by developing a novel automated approach for rapid and large-scale fabrication of VSA using a 3D printer and 96-well plate with high reproducibility for manufacturing VSA-based functional assays for evaluation of drug efficacy. In addition, the assay will be evaluated by assessing how it assesses for efficacy and cytotoxicity of drugs designed to treat atherosclerosis. “Development of this drug candidate evaluation assay leverages our expertise in bionanomaterials,” said Joseph Garner, Ph.D., Chief Executive Officer of Endomimetics. “The SBIR grant enables us to fully fund this development work so that no resources are diverted from development of applications for our core Bionanomatrix™ platform. If this research is successful, we plan on working with the U.S. Food and Drug Administration to validate the assay and partner with biotechnology and pharmaceutical companies to speed up and streamline the atherosclerosis drug development process. About Endomimetics:Endomimetics is a privately held Company founded to develop applications for its proprietary Bionanomatrix™ technology. The Bionanomatrix™, invented by bioengineering scientists and physicians at the University of Alabama Birmingham (UAB), is a peptide-based coating that can be engineered to perform a variety of functions, which may have broad application in medical device implantation and other surgical procedures. Endomimetics’ plans to develop different applications through the preclinical stage and then partner with medical device companies whose technology could benefit from Bionanomatrix™. The Company’s lead indication is the AVF GEL, which is designed to improve the maturation of arteriovenous fistulas. Other indications include coatings on stents and angioplasty balloons, dental direct pulp capping (DPC) and flow diverters. Additional information may be found on the Company’s website https://endomimetics.com/. About the Small Business Innovation Research (SBIR) ProgramThe Small Business Innovation Research (SBIR) program, created in 1982 through the Small Business Innovation Development Act and reauthorized in 2011, is one of the largest public–private partnerships in the United States. The SBIR program encourages U.S. small businesses with fewer than 500 employees to provide quality research and to develop new processes, products and technologies in support of the missions of the U.S. government. Administered by DHS S&T, the DHS SBIR Program, supports a full spectrum of SBIR initiatives serving all components. Contact Details:Company Contact:EndomimeticsDr. Joseph GarnerChief Executive Officerjng@endomimetics.com Investor Contacts:Eric Ando / Cameron RadinovicBurns McClellaneando@burnsmc.com / cradinovic@burnsmc.com Media Contact:Robert Flamm, Ph.D.Burns McClellanrflamm@burnsmc.com

临床1期

2024-09-17

·PRNewswire

The Inner Circle acknowledges, Lee C. Ferguson, DO, FACS as a Pinnacle Lifetime Member

MOBILE, Ala., Sept. 16, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon. Continue Reading Lee Ferguson Dr. Ferguson, a distinguished dual board-certified vascular surgeon and endovascular specialist, has been transforming vascular care in Mobile, Alabama, and its surrounding regions. He is a key member of Vascular Associates of South Alabama, LLC, renowned for his expertise in advanced, minimally invasive, endovascular techniques and traditional open surgery. Dr. Ferguson's unwavering commitment to patient-centered care reflects his belief in treating each patient as he would want his own family to be treated. His practice covers a wide spectrum of vascular conditions, including peripheral arterial disease, limb salvage, aortic aneurysms, carotid disease, varicose veins, and more. With years of dedication to the field of medicine, Dr. Ferguson holds a distinguished educational background, including a Bachelor of Science in Biology from the University of Arkansas at Monticello and a Doctor of Osteopathic Medicine (DO) from Pikeville College of Osteopathic Medicine. His training includes a general surgical residency at the University of South Alabama in Mobile and a fellowship in vascular surgery at the University of Mississippi Medical Center in Jackson. As a testament to his expertise, Dr. Ferguson is dual board-certified in vascular surgery and general surgery, a Diplomat to the American College of Surgeons (ACS), and a Fellow of the American College of Surgeons (FACS). He is also a Registered Physician in Vascular Interpretation (RPVI) and holds certifications in Advanced Cardiac Life Support (ACLS) and Basic Life Support (BLS). Dr. Ferguson's commitment extends beyond his practice, as he actively engages with professional organizations and medical societies, including the Alabama Medical Society, Mobile County Medical Society, American College of Surgeons, and Society of Vascular Surgeons. He shares his knowledge as a presenter at various medical conferences and co-authored a poster presentation for The Southeastern Surgical Congress meeting in 2013. Outside of medicine, Dr. Ferguson finds solace in the great outdoors. He enjoys hunting, fishing (both inshore and offshore), and sporting clays. His dedication to community service shines through his involvement with his local Mardi Gras Association, the Broad Street Restoration Society, and his role as a Mobile City Police Surgeon, where he volunteers his services for the local law enforcement community. Dr. Ferguson's family is a pillar of support, with his wife, Mrs. Kim Ferguson, and their two teenagers standing by his side. As a leading figure in vascular surgery, Dr. Ferguson's commitment to excellence in patient care and his contributions to the medical field continue to elevate the standard of vascular care in Mobile, Alabama, and the surrounding areas. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

100 项与 University of South Alabama 相关的药物交易

登录后查看更多信息

100 项与 University of South Alabama 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

siRNAs against RSV/PIV(University of South Alabama)	呼吸道合胞体病毒感染更多	临床前
MCI-062 ( RAS )	结直肠癌更多	临床前
OK-101 ( Chemerin receptors )	细胞因子释放综合征更多	临床前
Hydroxytyrosol ( HIV integrase )	前列腺癌更多	临床前
ADT-061 ( PDE10A )	肿瘤更多	临床前